The COVID-19 pandemic has constituted one of the most significant challenges to global healthcare and the international community in recent decades. Particular concern has been raised regarding the situation of the most vulnerable population groups, among which patients with oncological diseases are of paramount importance. Investigation of the COVID-19 clinical course in patients with cancer, as well as the optimization of patient management during the pandemic, represent critical areas of contemporary medicine. This review analyzes the findings of studies on the COVID-19 course among oncological patients. It demonstrates the gradual and dynamic evolution of both scientific and clinical understanding of this issue. From the initial alarming case reports in 2020 to systemic analyses of long-term outcomes in the period from 2023 to 2025, the medical and scientific communities have exhibited the capacity for rapid response to challenges posed by the novel coronavirus infection. During these years, effective clinical guidelines have been developed to provide a balance between the necessity of continuing antitumor therapy and minimizing the risk of SARS-CoV-2 infection. Currently, active study on the clinical and laboratory patterns of coronavirus infection in oncological patients is ongoing. KEYWORDS: oncology, COVID-19, SARS-CoV-2 infection, pandemic, vulnerable populations, vaccination, antitumor therapy. FOR CITATION: Kanner I.D., Usenko D.V. SARS-CoV-2 infection in patients with cancer: analyzing the pandemic outcomes. Russian Medical Inquiry. 2025;9(7):413–418 (in Russ.). DOI: 10.32364/2587-6821-2025-9-7-7
Kanner et al. (Wed,) studied this question.